Longitudinal 12-Month Follow-Up of a Male Infant with CYP21A2 Compound Heterozygous Genotype in China: A Case Report
American Journal of Perinatology Reports · 01.07.2025 · 15 (03) · e116-e123
DOI: 10.1055/a-2647-4369 ↗Kurz gefasst
Fallbericht in der Zeitschrift American Journal of Perinatology Reports, erschienen am 01.07.2025. Verfasst von Yi Yin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Prenatal Diagnosis, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technolog…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Congenital adrenal hyperplasia (CAH), predominantly caused by 21-hydroxylase deficiency (21-OHD), arises from mutations in CYP21A2. This frequently occurs via gene conversion events between CYP21A2 and its pseudogene, leading to impaired 21-hydroxylase activity and subsequent CAH manifestations. We encountered a case of classic CAH, characterized by electrolyte imbalances (hyponatremia: 125.10 mmol/L; hyperkalemia: 7.06 mmol/L), hyperpigmentation, and markedly elevated endocrine marker levels (17-hydroxyprogesterone: 319.91 nmol/L; adrenocorticotropic hormone: 611.00 pg/mL) in a male neonate. Through genetic diagnostics, we identified a maternal-derived deletion of CYP21A2 exons 1–7 combined with paternal-originated compound heterozygous mutations (c.293-13A/C>G in intron 2 and c.332_339 deletion in exon 3). Implementation of early genetic diagnosis revealed 21-OHD, and immediate therapeutic intervention was initiated within 11 days after the birth of the patient. Long-term treatment, including oral hydrocortisone, fludrocortisone, and 0.9% sodium chloride, provided effective clinical control and management, as determined by longitudinal follow-up monitoring of serum electrolyte profiles, endocrine function, and physical development. This case provided critical insights into the genotype–phenotype correlations of classic 21-OHD. Our findings will contribute to precision medicine for managing this rare endocrine disorder during critical infancy periods, and emphasize the need for comprehensive genetic diagnostics and educational values for neonatal 21-OHD care.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Prenatal Diagnosis, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
- Department of Neonatology, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
- Department of Medical Laboratory, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
- Department of Neonatal Disease Screening, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
ORCID-Profile: Yi Yin
Zitieren
APA
Yin, Y., Huang, X., Shi, Y., Huang, C., Yu, J., & Liu, Q. (2025). Longitudinal 12-Month Follow-Up of a Male Infant with CYP21A2 Compound Heterozygous Genotype in China: A Case Report. American Journal of Perinatology Reports, 15(03), e116-e123. https://doi.org/10.1055/a-2647-4369
Vancouver
Yin Y, Huang X, Shi Y, Huang C, Yu J, Liu Q. Longitudinal 12-Month Follow-Up of a Male Infant with CYP21A2 Compound Heterozygous Genotype in China: A Case Report. American Journal of Perinatology Reports. 2025;15(03):e116-e123. doi:10.1055/a-2647-4369
BibTeX
@article{Yin2025,
author = {Yin, Yi and Huang, Xinyue and Shi, Yun and Huang, Cheng and Yu, Jian and Liu, Qingsong},
title = {Longitudinal 12-Month Follow-Up of a Male Infant with CYP21A2 Compound Heterozygous Genotype in China: A Case Report},
journal = {American Journal of Perinatology Reports},
year = {2025},
volume = {15},
number = {03},
pages = {e116--e123},
doi = {10.1055/a-2647-4369}
}
EUVIMED